In vivo selection of respiratory syncytial viruses resistant to palivizumab

Journal of Virology

Volumn 79, Issue 7, 2005, Pages 3962-3968

  Zhao, Xiaodong ^a   Sullender, Wayne M ^a,b,c  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; PALIVIZUMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL WARFARE; CELL CULTURE; CONTROLLED STUDY; DRUG SENSITIVITY; F GENE; GENE MUTATION; GENETIC SELECTION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VIVO STUDY; INOCULATION; LUNG; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROPHYLAXIS; RAT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROGENESIS; VIRUS GENE; VIRUS INFECTION; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CELLS, CULTURED; DNA MUTATIONAL ANALYSIS; DNA, COMPLEMENTARY; DRUG RESISTANCE, VIRAL; HUMANS; LUNG; POINT MUTATION; RATS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RNA, VIRAL; SELECTION (GENETICS); SEQUENCE ANALYSIS, DNA; SIGMODONTINAE; VIRAL PROTEINS;

EID: 15244339450     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.7.3962-3968.2005     Document Type: Article

References (36)

1. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. 2003. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 112:1442-1446.
2. Anderson, L., J. Hierholzer, P. Bingham, and Y. Stone. 1985. Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay. J. Clin. Microbiol. 22:1050-1052.
3. Arbiza, J., G. Taylor, J. Lopez, J. Furze, S. Wyld, P. Whyte, E. Stott, G. Wertz, W. Sullender, M. Trudel, and J. Melero. 1992. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J. Gen. Virol. 73:2225-2234.
4. Arias, A., E. Lazaro, C. Escarmis, and E. Domingo. 2001. Molecular intermediates of fitness gain of an RNA virus: characterization of a mutant spectrum by biological and molecular cloning. J. Gen. Virol. 82:1049-1060.
5. Beeler, J., and K. Van Wyke Coelingh. 1989. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus effect of mutation upon fusion function. J. Virol. 63:2941-2950.
6. Boeckh, M., M. Berrey, R. Bowden, S. Crawford, J. Balsley, and L. Corey. 2001. Phase 1 evaluation of the respiratory syncytial virus specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J. Infect. Dis. 184:350-354.
7. Carman, W., A. Zanett, P. Karayiannis, J. Waters, G. Manzíllo, E. Tanzi, A. Zuckerman, and H. Thomas. 1990. Vaccine-induced escape mutant of hepatitis B virus. Lancet 336:325-329.
8. Collins, P., R. Chanock, and B. Murphy. 2000. Respiratory syncytial virus, p. 1443-1485. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed., vol. 1. Lippincott Williams & Wilkins, Philadelphia, Pa.
9. Crowe, J., C. Firestone, R. Crim, J. Beeler, K. Coelingh, C. Barbas, D. Burton, R. Chanock, and B. Murphy. 1998. Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody Fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein. Virology 252:373-375.
10. DeVincenzo, J., C. Hall, D. Kimberlin, P. Sanchez, W. Rodriguez, B. Jantausch, L. Corey, J. Kahn, J. Englund, J. Suzich, F. Palmer-Hill, L. Branco, S. Johnson, N. Patel, and F. Piazza. 2004. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J. Infect. Dis. 190:975-978.
11. Domingo, E., and J. Holland. 1994. Mutation rates and rapid evolution of RNA viruses, p. 161-184. In S. Morse (ed.), The evolutionary biology of viruses. Raven Press, New York, N.Y.
12. El Saleeby, C., J. Suzich, M. Conley, and J. DeVincenzo. 2004. Quantitative effects of palivizumab and donor-derived T cells on chronic respiratory syncytial virus infection, lung disease, and fusion glycoprotein amino acid sequences in a patient before and after bone marrow transplantation. Clin. Infect. Dis. 39:e17-e20.
13. Fischaut, M., D. Tubergen, and K. McIntosh. 1980. Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. J. Pediatr. 96:179-186.
14. Fleming, D. M., and K. Cross. 1993. Respiratory syncytial virus or influenza? Lancet 342:1507-1510.
15. Garcia-Barreno, B., A. Portela, T. Delgado, J. Lopez, and J. Melero. 1990. Frame shift mutations as a novel mechanism for the generation of neutralization resistant mutants of human respiratory syncytial virus. EMBO J. 9:4181-4187.
16. Hall, C., K. Powell, N. MacDonald, C. Gala, M. Menegus, S. Suffin, and H. Cohen. 1986. Respiratory syncytial viral infection in children with compromised immune function. N. Engl. J. Med. 315:77-81.
17. Hamre, D., C. Loosli, and P. Gerber. 1958. Antigenic variants of influenza A virus (PR8 strain). III. Serological relationships of a line of variants derived in sequence in mice given homologous vaccine. J. Exp. Med. 107:829-844.
18. Hyslop, N. G., and R. Fagg. 1965. Isolation of variants during passage of a strain of foot-and-mouth disease virus in partly immunized cattle. J. Hyg. 63:357-368.
19. IMPACT. 1998. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitatization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:531-537.
20. Johnson, R., G. Prince, S. Suffin, R. Horswood, and R. Chanock. 1982. Respiratory syncytial virus infection in cyclophosphamide-treated cotton rats. Infect. Immun. 37:369-373.
21. Johnson, S., C. Oliver, G. Prince, V. Hemming, D. Pfarr, S. Wang, M. Dormitzer, J. O. Grady, S. Koenig, J. Tamura, R. Woods, G. Bansal, D. Couchenour, E. Tsao, W. Hall, and J. Young. 1997. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176:1215-1224.
22. Lopez, J., R. Bustos, C. Orvell, M. Berois, J. Arbiza, B. Garcia-Barreno, and J. Melero. 1998. Antigenic structure of human respiratory syncytial virus fusion glycoprotein. J. Virol. 72:6922-6928.
23. Lopez, J., C. Penas, B. Garcia-Barreno, J. Melero, and A. Portela. 1990. Location of a highly conserved neutralizing epitope in the F glycoprotein of human respiratory syncytial virus. J. Virol. Methods 64:927-930.
24. Lopez-Bueno, A., M. Mateu, and J. Almedral. 2003. High mutant frequency in populations of a DNA virus allows evasion from antibody therapy in an immunodeficient host. J. Virol. 77:2701-2708.
25. Malley, R., J. DeVincenzo, O. Ramilo, P. Dennehy, H. Meissner, W. Gruber, P. Sanchez, H. Jafri, J. Balsley, D. Carlin, S. Buckingham, L. Vernacchio, and D. Ambrosino. 1998. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J. Infect. Dis. 178:1555-1561.
26. Mathur, U., D. Bentley, and C. Hall. 1980. Concurrent respiratory syncytial virus and influenza A infections in the institutionalized elderly and chronically ill. Ann. Intern. Med. 93:49-52.
27. Ottolini, M., S. Curtis, A. Mathews, S. Ottolini, and G. Prince. 2002. Palivizumah is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model. Bone Marrow Transplant. 29:117-120.
28. Protzer-Knolle, U., U. Naumann, R. Bartenschlager, T. Berg, U. Hopf, K. Hermann, M. zum-Büschenfelde, P. Neuhaus, and G. Gerken. 1998. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 27:254-263.
29. Schild, G., J. S. Oxford, J. C. De Jong, and R. Webster. 1983. Evidence for host-cell selection of influenza virus antigenic variants. Nature 303:706-709.
30. Steihm, E., and M. Keller. 2004. Passive immunization, p. 3182-3220. In R. D. Feigin, J. D. Cherry, G. J. Demmler, and S. L. Kaplan (ed.), Textbook of pediatric infectious diseases, 5th ed., vol. 2. Sauders, Philadelphia, Pa.
31. Sullender, W., and K. Edwards. 1999. Mutations of respiratory syncytial virus attachment glycoprotein G associated with resistance to neutralization by primate polyclonal antibodies. Virology 264:230-236.
32. Taboga, O., C. Tami, E. Carrillo, J. Nunez, A. Rodriguez, J. Saiz, E. Blanco, M. Valero, X. Roig, J. Camarero, D. Andreu, M. Mateu, E. Giralt, E. Domingo, F. Sobrino, and E. Palma. 1997. A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants. J. Virol. 71:2606-2614.
33. Walsh, E., A. Falsey, and W. Sullender. 1998. Monoclonal antibody neutralization escape mutants of respiratory syncytial virus with unique alterations in the attachment (G) protein. J. Gen. Virol. 79:479-487.
34. Wong, D., M. Rosenband, K. Hovey, and P. Ogra. 1985. Respiratory syncytial virus infection in immunosuppressed animals: implications in human infection. J. Med. Virol. 17:359-370.
35. Zhao, X., F. Chen, A. G. Megaw, and W. Sullender. 2004. Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants. J. Infect. Dis. 190:1941-1946.
36. Zhao, X., F. Chen, and W. Sullender. 2004. Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology 318:608-612.